Cancer Family
Secondary Neoplasm
CI-CAN-00000050Explore in graph →
Non-malignant4,276 active trials56 approved drugs532 evidence items
- NCIt
- C36255
Loading cancer entity…
Cancer Family
CI-CAN-00000050Explore in graph →
Clinical trials
14,673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06999837 | [68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.(HIMIKO) | recruiting | N/A | 40 | Nantes University HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07120295 | Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories | recruiting | Phase 4 | 75 | University of Colorado, DenverOTHER | 1 | Sep 3, 2026 |
| clinicaltrials |
| NCT07156227 | Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07413939 | RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive(BREnnA) | recruiting | Phase 2 / Phase 3 | 650 | Hoffmann-La RocheINDUSTRY | 25 | Sep 3, 2026 | clinicaltrials |
| NCT07446257 | THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | recruiting | Early Phase 1 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07509099 | Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC | not yet recruiting | Phase 3 | 316 | Ji DongmeiOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07509333 | MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients | recruiting | N/A | 2,000 | West China HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07644559 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | recruiting | Phase 2 | 180 | Verastem, Inc.INDUSTRY | 3 | Sep 3, 2026 | clinicaltrials |
| NCT07650773 | CHARM Hepatocellular Carcinoma MEA Study | recruiting | — | 4,000 | AstraZenecaINDUSTRY | 7 | Sep 3, 2026 | clinicaltrials |
| NCT07801027 | A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) | not yet recruiting | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07801235 | HYperfractionated Radiation Therapy Versus Concurrent Chemoradiation for Head and Neck Cancer (HYTC) | recruiting | N/A | 604 | King Hussein Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07801287 | Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802197 | Neoadjuvant Radiotherapy vs Upfront Surgery in Locally Advanced Proximal Rectal Cancer(PRELUDE) | recruiting | N/A | 100 | Istanbul UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802821 | A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 556 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07803159 | Frailty, Immunonutrition, Surgery Type, and Biologic Recovery in Elderly Gastric Cancer | not yet recruiting | — | 328 | Kocaeli City HospitalOTHER_GOV | 1 | Sep 3, 2026 | clinicaltrials |
| NCT02750826 | Breast Cancer WEight Loss Study (BWEL Study) | active not recruiting | Phase 3 | 3,177 | Alliance for Clinical Trials in OncologyOTHER | 4 | Sep 2, 2026 | clinicaltrials |
| NCT03317405 | Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery | active not recruiting | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03762759 | Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes | active not recruiting | Phase 2 | 140 | Emory UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04047251 | A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma | active not recruiting | Phase 1 | 96 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05080673 | Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps(FORTE) | recruiting | N/A | 9,500 | NRG OncologyOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | recruiting | Phase 1 | 336 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05247905 | Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial | active not recruiting | Phase 2 | 31 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05286814 | PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma | recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 2, 2026 | clinicaltrials |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | recruiting | — | 2,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05837767 | A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue | recruiting | N/A | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05964504 | Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry) | recruiting | — | 150 | University of California, San FranciscoOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06557057 | Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk | recruiting | — | 81 | Mayo ClinicOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06661720 | Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer(STRIKE) | recruiting | Phase 3 | 1,040 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06673017 | PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | Phase 1 | 26 | PanTher TherapeuticsINDUSTRY | 2 | Sep 2, 2026 | clinicaltrials |
| NCT06745609 | Prehabilitation Prior to Surgery for Kidney Tumors(Pre-KiT) | active not recruiting | N/A | 60 | Herlev and Gentofte HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06761937 | Thermotherapy for Locally Advanced Head and Neck Cancer(TANCA-I) | active not recruiting | Phase 1 | 2 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06762080 | Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis | active not recruiting | Phase 1 / Phase 2 | 36 | Guangzhou Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06809530 | Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis | active not recruiting | Phase 1 / Phase 2 | 34 | Guangzhou Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06931340 | Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | recruiting | Phase 3 | 1,260 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07024615 | A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer | recruiting | Phase 1 | 25 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07143487 | Family Communications After Genetic Testing | recruiting | N/A | 4,186 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT07200830 | Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial | recruiting | Phase 3 | 1,524 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07216105 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 119 | Fate TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07292298 | Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates | recruiting | Phase 2 | 44 | University of Colorado, DenverOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07463248 | PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy | recruiting | Phase 2 | 64 | Wang XinOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07485569 | Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial(REPOTHYROID-II) | active not recruiting | Phase 1 | 10 | Radboud University Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07613151 | Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study(NAPOLI) | recruiting | — | 250 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07690618 | Thermotherapy for Head and Neck Cancer Patients(TANCAP-I) | recruiting | Phase 1 | 30 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07766226 | Online Sharing for Head & Neck Cancer Support | recruiting | N/A | 120 | West China HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07783477 | A Study of Armored CAR T Cells in People With Cancer | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07786792 | Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCC(MUSE2) | not yet recruiting | — | 400 | Shanghai Zhongshan HospitalOTHER | 0 | Sep 2, 2026 | clinicaltrials |
| NCT07795437 | GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma | recruiting | N/A | 100 | Peking University First HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Sep 3, 2026source: clinicaltrials